Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial
Authors:
- Amadeus InvestigatorsAIAmadeus Investigators
- M G BousserMBM G Bousser
- J BouthierJBJ Bouthier
- H R BüllerHBH R Büller
- A T CohenACA T Cohen
- H CrijnsHCH Crijns
- B L DavidsonBDB L Davidson
- J HalperinJHJ Halperin
- G HankeyGHG Hankey
- S LevySLS Levy
- V PengoVPV Pengo
- P PrandoniPPP Prandoni
- 1 January 2008
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 371 (9609) , 315-321
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive SummaryJACC, 2006
- Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trialThe Lancet, 2006
- New anticoagulantsJournal of Thrombosis and Haemostasis, 2005
- Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial FibrillationJAMA, 2005
- Antithrombotic Therapy in Atrial FibrillationChest, 2004
- A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluationJournal of Thrombosis and Haemostasis, 2004
- Utility and pitfalls of some statistical methods in active controlled clinical trialsControlled Clinical Trials, 2002
- Atrial Fibrillation and Thromboembolism: A Decade of Progress in Stroke PreventionAnnals of Internal Medicine, 1999
- Antithrombotic Therapy To Prevent Stroke in Patients with Atrial FibrillationAnnals of Internal Medicine, 1999
- Biochemical and Pharmacological Properties of SANORG 34006, a Potent and Long-Acting Synthetic PentasaccharideBlood, 1998